Table 4 Lipid levels according to rs688,... | American Society of Hematology

Table 4

Lipid levels according to rs688, rs2228671, and rs1122608 genotypes in the whole study population (n = 983) and in subjects without lipid-lowering therapies (n = 693)

	Total cholesterol, mM	P	LDL cholesterol, mM	P	HDL cholesterol, mM	P	Total cholesterol/HDL ratio	P	Triglycerides, mM	P
Whole study population (n = 983)
rs688, %
CC (n = 317)	5.60 ± 1.06		3.71 ± 0.97		1.27 ± 0.34		4.73 ± 1.51		1.78 ± 0.85
CT (n = 548)	5.74 ± 1.13	.169*	3.79 ± 0.96	.511*	1.29 ± 0.36	.216*	4.78 ± 1.63	.555*	1.83 ± 1.11	.444*
TT (n = 208)	5.68 ± 1.17		3.79 ± 1.03		1.23 ± 0.33		4.89 ± 1.51		1.90 ± 1.24
Carrrier T (vs CC)	5.72 ± 1.14	.104†	3.79 ± 0.98	.246†	1.27 ± 0.35	.935†	4.82 ± 1.59	.470†	1.85 ± 1.15	.329†
rs2228671, %‡
CC (n = 757)	5.71 ± 1.12		3.79 ± 0.98		1.26 ± 0.35		4.85 ± 1.59		1.86 ± 1.12
CT (n = 189)	5.54 ± 1.09	.172*	3.64 ± 0.93	.179*	1.31 ± 0.35	.240*	4.52 ± 1.46	.043*	1.71 ± 0.84	.210*
TT (n = 12)	5.77 ± 1.12		3.88 ± 0.98		1.25 ± 0.41		5.01 ± 1.65		2.04 ± 1.13
Carrrier T (vs CC)	5.56 ± 1.09	.081†	3.65 ± 0.93	.091†	1.31 ± 0.35	.110†	4.55 ± 1.48	.022†	1.73 ± 0.86	.149†
rs1122608, %§
GG (n = 506)	5.63 ± 1.12		3.72 ± 0.97		1.25 ± 0.34		4.82 ± 1.44		1.87 ± 1.02
GT (n = 351)	5.70 ± 1.08	.080*	3.78 ± 0.96	.150*	1.30 ± 0.36	.105*	4.69 ± 1.47	.279*	1.79 ± 1.15	.406*
TT (n = 59)	5.36 ± 0.87		3.51 ± 0.68		1.29 ± 0.35		4.54 ± 1.66		1.70 ± 0.95
Carrrier T (vs GG)	5.65 ± 1.06	.766†	3.74 ± 0.93	.836†	1.30 ± 0.36	.035†	4.67 ± 1.50	.125†	1.78 ± 1.12	.230†
Subjects without lipid-lowering therapies (n = 693)
rs688, %
CC (n = 222)	5.66 ± 1.06		3.79 ± 0.98		1.28 ± 0.36		4.74 ± 1.48		1.71 ± 0.79
CT (n = 325)	5.74 ± 1.05	.539*	3.79 ± 0.88	.684*	1.30 ± 0.38	.673*	4.78 ± 1.68	.701*	1.80 ± 1.00	.487*
TT (n = 146)	5.78 ± 1.17		3.87 ± 1.05		1.26 ± 0.35		4.88 ± 1.48		1.82 ± 0.98
Carrrier T (vs CC)	5.75 ± 1.09	.289†	3.81 ± 0.94	.792†	1.29 ± 0.37	.909†	4.81 ± 1.61	.578†	1.80 ± 1.00	.239†
rs2228671, %‖
CC (n = 528)	5.78 ± 1.08		3.86 ± 0.96		1.28 ± 0.37		4.86 ± 1.60		1.80 ± 0.96
CT (n = 134)	5.55 ± 1.07	.065*	3.64 ± 0.94	.055*	1.33 ± 0.37	.387*	4.47 ± 1.47	.046*	1.62 ± 0.76	.073*
TT (n = 11)	5.95 ± 0.98		4.06 ± 0.86		1.29 ± 0.41		5.08 ± 1.72		2.07 ± 1.17
Carrrier T (vs CC)	5.58 ± 1.06	.045†	3.67 ± 0.94	.041†	1.33 ± 0.37	.182†	4.52 ± 1.49	.029†	1.65 ± 0.80	.095†
rs1122608, %¶
GG (n = 349)	5.72 ± 1.09		3.80 ± 0.96		1.26 ± 0.36		4.86 ± 1.47		1.85 ± 1.02
GT (n = 253)	5.72 ± 1.07	.074*	3.79 ± 0.96	.167*	1.32 ± 0.37	.185*	4.62 ± 1.37	.059*	1.68 ± 0.79	.049*
TT (n = 44)	5.34 ± 0.90		3.50 ± 0.72		1.30 ± 0.35		4.43 ± 1.40		1.63 ± 0.75
Carrrier T (vs GG)	5.66 ± 1.05	.453†	3.74 ± 0.93	.455†	1.32 ± 0.37	.073†	4.59 ± 1.37	.025†	1.67 ± 0.79	.015†

	Total cholesterol, mM	P	LDL cholesterol, mM	P	HDL cholesterol, mM	P	Total cholesterol/HDL ratio	P	Triglycerides, mM	P
Whole study population (n = 983)
rs688, %
CC (n = 317)	5.60 ± 1.06		3.71 ± 0.97		1.27 ± 0.34		4.73 ± 1.51		1.78 ± 0.85
CT (n = 548)	5.74 ± 1.13	.169*	3.79 ± 0.96	.511*	1.29 ± 0.36	.216*	4.78 ± 1.63	.555*	1.83 ± 1.11	.444*
TT (n = 208)	5.68 ± 1.17		3.79 ± 1.03		1.23 ± 0.33		4.89 ± 1.51		1.90 ± 1.24
Carrrier T (vs CC)	5.72 ± 1.14	.104†	3.79 ± 0.98	.246†	1.27 ± 0.35	.935†	4.82 ± 1.59	.470†	1.85 ± 1.15	.329†
rs2228671, %‡
CC (n = 757)	5.71 ± 1.12		3.79 ± 0.98		1.26 ± 0.35		4.85 ± 1.59		1.86 ± 1.12
CT (n = 189)	5.54 ± 1.09	.172*	3.64 ± 0.93	.179*	1.31 ± 0.35	.240*	4.52 ± 1.46	.043*	1.71 ± 0.84	.210*
TT (n = 12)	5.77 ± 1.12		3.88 ± 0.98		1.25 ± 0.41		5.01 ± 1.65		2.04 ± 1.13
Carrrier T (vs CC)	5.56 ± 1.09	.081†	3.65 ± 0.93	.091†	1.31 ± 0.35	.110†	4.55 ± 1.48	.022†	1.73 ± 0.86	.149†
rs1122608, %§
GG (n = 506)	5.63 ± 1.12		3.72 ± 0.97		1.25 ± 0.34		4.82 ± 1.44		1.87 ± 1.02
GT (n = 351)	5.70 ± 1.08	.080*	3.78 ± 0.96	.150*	1.30 ± 0.36	.105*	4.69 ± 1.47	.279*	1.79 ± 1.15	.406*
TT (n = 59)	5.36 ± 0.87		3.51 ± 0.68		1.29 ± 0.35		4.54 ± 1.66		1.70 ± 0.95
Carrrier T (vs GG)	5.65 ± 1.06	.766†	3.74 ± 0.93	.836†	1.30 ± 0.36	.035†	4.67 ± 1.50	.125†	1.78 ± 1.12	.230†
Subjects without lipid-lowering therapies (n = 693)
rs688, %
CC (n = 222)	5.66 ± 1.06		3.79 ± 0.98		1.28 ± 0.36		4.74 ± 1.48		1.71 ± 0.79
CT (n = 325)	5.74 ± 1.05	.539*	3.79 ± 0.88	.684*	1.30 ± 0.38	.673*	4.78 ± 1.68	.701*	1.80 ± 1.00	.487*
TT (n = 146)	5.78 ± 1.17		3.87 ± 1.05		1.26 ± 0.35		4.88 ± 1.48		1.82 ± 0.98
Carrrier T (vs CC)	5.75 ± 1.09	.289†	3.81 ± 0.94	.792†	1.29 ± 0.37	.909†	4.81 ± 1.61	.578†	1.80 ± 1.00	.239†
rs2228671, %‖
CC (n = 528)	5.78 ± 1.08		3.86 ± 0.96		1.28 ± 0.37		4.86 ± 1.60		1.80 ± 0.96
CT (n = 134)	5.55 ± 1.07	.065*	3.64 ± 0.94	.055*	1.33 ± 0.37	.387*	4.47 ± 1.47	.046*	1.62 ± 0.76	.073*
TT (n = 11)	5.95 ± 0.98		4.06 ± 0.86		1.29 ± 0.41		5.08 ± 1.72		2.07 ± 1.17
Carrrier T (vs CC)	5.58 ± 1.06	.045†	3.67 ± 0.94	.041†	1.33 ± 0.37	.182†	4.52 ± 1.49	.029†	1.65 ± 0.80	.095†
rs1122608, %¶
GG (n = 349)	5.72 ± 1.09		3.80 ± 0.96		1.26 ± 0.36		4.86 ± 1.47		1.85 ± 1.02
GT (n = 253)	5.72 ± 1.07	.074*	3.79 ± 0.96	.167*	1.32 ± 0.37	.185*	4.62 ± 1.37	.059*	1.68 ± 0.79	.049*
TT (n = 44)	5.34 ± 0.90		3.50 ± 0.72		1.30 ± 0.35		4.43 ± 1.40		1.63 ± 0.75
Carrrier T (vs GG)	5.66 ± 1.05	.453†	3.74 ± 0.93	.455†	1.32 ± 0.37	.073†	4.59 ± 1.37	.025†	1.67 ± 0.79	.015†

By analysis of variance.

†

By t test.

‡

Data about rs2228671 genotype were available for 958 subjects.

Data about rs1122608 genotype were available for 916 subjects.

‖

Data about rs2228671 genotype were available for 673 subjects without lipid-lowering therapies.

Data about rs1122608 genotype were available for 646 subjects without lipid-lowering therapies.

View Large

This Feature Is Available To Subscribers Only